Indivior PLC (INDV) - Total Assets
Based on the latest financial reports, Indivior PLC (INDV) holds total assets worth GBX1.45 Billion GBX (≈ $176.67K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore INDV debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Indivior PLC - Total Assets Trend (2011–2024)
This chart illustrates how Indivior PLC's total assets have evolved over time, based on quarterly financial data. See INDV net assets for net asset value and shareholders' equity analysis.
Indivior PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Indivior PLC's total assets of GBX1.45 Billion consist of 63.6% current assets and 36.4% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 24.2% |
| Accounts Receivable | GBX254.00 Million | 19.3% |
| Inventory | GBX178.00 Million | 13.5% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX5.00 Million | 0.4% |
| Goodwill | GBX2.00 Million | 0.2% |
Asset Composition Trend (2011–2024)
This chart illustrates how Indivior PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Indivior PLC market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Indivior PLC's current assets represent 63.6% of total assets in 2024, an increase from 58.9% in 2011.
- Cash Position: Cash and equivalents constituted 24.2% of total assets in 2024, up from 1.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 24.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 19.3% of total assets.
Indivior PLC Competitors by Total Assets
Key competitors of Indivior PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Alkermes plc
F:8AK
|
Germany | €4.26 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
Indivior PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.90 | 0.85 | 1.82 |
| Quick Ratio | 0.76 | 0.68 | 1.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-105.00 Million | GBX-148.00 Million | GBX543.00 Million |
Indivior PLC - Advanced Valuation Insights
This section examines the relationship between Indivior PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 141.02 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -32.5% |
| Total Assets | GBX1.32 Billion |
| Market Capitalization | $18.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Indivior PLC's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Indivior PLC's assets decreased by 32.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Indivior PLC (2011–2024)
The table below shows the annual total assets of Indivior PLC from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX1.32 Billion ≈ $160.48K |
-32.50% |
| 2023-12-31 | GBX1.95 Billion ≈ $237.75K |
+10.46% |
| 2022-12-31 | GBX1.77 Billion ≈ $215.24K |
-3.44% |
| 2021-12-31 | GBX1.83 Billion ≈ $222.90K |
+19.66% |
| 2020-12-31 | GBX1.53 Billion ≈ $186.28K |
-7.32% |
| 2019-12-31 | GBX1.65 Billion ≈ $201.00K |
+6.79% |
| 2018-12-31 | GBX1.55 Billion ≈ $188.23K |
+7.13% |
| 2017-12-31 | GBX1.44 Billion ≈ $175.69K |
+19.44% |
| 2016-12-31 | GBX1.21 Billion ≈ $147.10K |
+29.03% |
| 2015-12-31 | GBX937.00 Million ≈ $114.01K |
+25.44% |
| 2014-12-31 | GBX747.00 Million ≈ $90.89K |
+75.35% |
| 2013-12-31 | GBX426.00 Million ≈ $51.83K |
-23.52% |
| 2012-12-31 | GBX557.00 Million ≈ $67.77K |
-0.36% |
| 2011-12-31 | GBX559.00 Million ≈ $68.01K |
-- |
About Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more